4/18
07:23 am
cmmb
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis [Yahoo! Finance]
High
Report
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis [Yahoo! Finance]
4/18
07:00 am
cmmb
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
High
Report
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
4/2
07:05 am
cmmb
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024 [Yahoo! Finance]
Low
Report
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024 [Yahoo! Finance]
4/2
07:00 am
cmmb
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
Low
Report
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
3/25
07:21 am
cmmb
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis [Yahoo! Finance]
Medium
Report
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis [Yahoo! Finance]
3/25
07:06 am
cmmb
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
Medium
Report
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
3/7
07:03 am
cmmb
Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update [Yahoo! Finance]
Medium
Report
Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update [Yahoo! Finance]
3/7
07:00 am
cmmb
Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update
Medium
Report
Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update
3/5
07:00 am
cmmb
Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference
Low
Report
Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference
2/28
07:10 am
cmmb
AxoSim Appoints Two Biotech Industry Veterans as Co-Chairs of Its Board of Directors [Yahoo! Finance]
Low
Report
AxoSim Appoints Two Biotech Industry Veterans as Co-Chairs of Its Board of Directors [Yahoo! Finance]
2/28
07:00 am
cmmb
AxoSim Appoints Two Biotech Industry Veterans as Co-Chairs of Its Board of Directors
Low
Report
AxoSim Appoints Two Biotech Industry Veterans as Co-Chairs of Its Board of Directors
2/20
07:08 am
cmmb
Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases [Yahoo! Finance]
High
Report
Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases [Yahoo! Finance]
2/20
07:00 am
cmmb
Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases
Medium
Report
Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases
2/14
07:00 am
cmmb
Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
Low
Report
Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
2/5
07:07 am
cmmb
Chemomab Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Chemomab Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
2/5
07:00 am
cmmb
Chemomab Therapeutics to Participate in Upcoming Investor Conferences
Medium
Report
Chemomab Therapeutics to Participate in Upcoming Investor Conferences
1/30
07:18 am
cmmb
Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis [Yahoo! Finance]
Medium
Report
Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis [Yahoo! Finance]
1/30
07:00 am
cmmb
Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
Medium
Report
Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
1/22
05:01 pm
cmmb
Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - MediciNova, Eli Lilly and Company, AstraZeneca, Madrigal Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Pfizer
Low
Report
Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - MediciNova, Eli Lilly and Company, AstraZeneca, Madrigal Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Pfizer
1/22
05:01 pm
cmmb
Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - MediciNova, Eli Lilly and Company, AstraZeneca, Madrigal Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Pfizer
Low
Report
Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - MediciNova, Eli Lilly and Company, AstraZeneca, Madrigal Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Pfizer